Medicare Drug Prices Much Higher Than Other Countries and Other Federal Programs, According to New Policy Paper
To hear it from the pharmaceutical industry, Medicare Part D, the federal program that helps American seniors and the disabled cover medication costs, is a highly popular, successful, low-cost program. That’s bunk. According to a new paper, written by authors Marc-Andrew Gagon, PhD. and Sidney Wolfe, MD (Carleton University’s School of Public Policy and Administration and Public Citizen, respectively), drug prices covered under Medicare Part D are wildly inflated compared to drug prices in all other countries. Ok. We knew that already. That’s why seniors continue to import medication from other countries! But seriously, this report includes fresh data and critical analysis to reminds us, and hopefully convince Congress, that not only are we paying too much as taxpayers and consumers but Americans often cannot afford to take prescribed medication at all, and that leads to more hospitalizations and higher healthcare costs.
We’ve noted on many occasions the government’s survey data showing that about five million Americans import prescription drugs for personal use due to cost. About 750,000 are seniors, most who are subject to the coverage gap known as the “doughnut hole” of Part D, which, despite improvements under Obamacare, still leads to millions of seniors struggling to afford medication. Their decision to buy more affordable medication internationally makes sense. According to the new report, even the rebated brand name drugs under Part D are almost twice (198%) the cost paid in countries that make up the Organization of Economic Cooperation and Development (OECD) – the most advanced economies.
The report is called “Mirror, Mirror, on the Wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and U.S. government programs.” You can find it here. (more…)gagnon, OECD, Part D, public citizne, seniors, sidney wolfe